{'fraction_non_alphanumeric': 0.06090026478375993, 'fraction_numerical': 0.05560458958517211, 'mean_word_length': 4.7272727272727275, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Glucose lowering properties of Cordymax‐7 in DIO mice with impaired glucose metabolism

CordyMax (CM), a fermented product of Cordyceps sinensis, has a function of improving insulin sensitivity and glucose metabolism in animals and humans (JACM 8:309 & 8:315, 2002; CJCP 16:274, 2007). We investigated the effect of CM7 on improving glucose metabolism in DIO mice. Male ICR mice were fed high‐calorie‐diet (HCD) for 14 weeks to develop Metabolic Syndrome X (MSX) with glucose intolerance. MSX mice were randomized into 5 groups, receiving vehicle, positive drug (Metformin Hydrochloride 0.5g/kg) or CM7 (0.25, 0.5, or 1.5g/kg) for 28 days. Body weight was monitored every week. Fasting blood glucose (FBG) and oral glucose tolerance test (OGTT) were assessed at Day 28. Compared to controls, CM7 (0.5g/kg) decreased FBG by 19.3% (p=0.041) and 180‐min blood glucose by 32.6% (p=0.024) after oral dextrose bolus (1g/kg). Our data suggests that CM7 is effective in improving glucose metabolism in DIO‐MSX mice. Other animal models will be used to further assess the efficacy of CM7 in glucose metabolism before clinical tests in humans.